Delving into the Latest Updates on NovaLead Pharma Pvt Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Cardiovascular Diseases

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5

Top 5 Target	Count

β1-adrenergic receptor(Beta-1 adrenergic receptor)	1

The purpose of the current Study is to determine the safety and effectiveness of Galnobax® plus Standard of Care versus only Standard of Care, in treating Diabetic Foot Ulcers (DFU). In addition, Study is designed to investigate the safety of Galnobax® vehicle for establishing non-deleterious effects of Vehicle on wound healing in the Subjects with DFU. The study is being conducted in 350 subjects being recruited in about 30 centers in India.

Start Date26 Dec 2018

Sponsor / Collaborator

NovaLead Pharma Pvt Ltd.

CTRI/2018/11/016295 / RecruitingPhase 3

A Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (GALNOBAXÂ®) in Treating Diabetic Foot Ulcers.

Start Date10 Nov 2018

Sponsor / Collaborator

NovaLead Pharma Pvt Ltd.

NCT01113515 / CompletedPhase 1/2

An Interventional, Placebo-Controlled, Randomized, Double-blinded Dose Comparison, Phase I/II Study to Determine the Safety and Efficacy of a New Gel Formulation of Esmolol Hydrochloride (Galnobax®) for the Treatment of Diabetic Foot Ulcer (DFU)

The purpose of this study is to determine safety and efficacy of a new gel formulation of Esmolol hydrochloride (Galnobax®) for the treatment of Diabetic Foot Ulcer (DFU). The study will compare number and types of adverse events occured, rates of wound closure and percentage of wounds closed in Galnobax treated groups versus placebo group.

Start Date20 Feb 2014

Sponsor / Collaborator

NovaLead Pharma Pvt Ltd.

100 Clinical Results associated with NovaLead Pharma Pvt Ltd.

Login to view more data

0 Patents (Medical) associated with NovaLead Pharma Pvt Ltd.

Login to view more data

5

Literatures (Medical) associated with NovaLead Pharma Pvt Ltd.

30 Jun 2019·European Journal of Organic Chemistry

Synthesis of 4‐C‐β‐D‐Glucosylated Isoliquiritigenin and Analogues for Aldose Reductase Inhibition Studies

Author: Mukhopadhyay, Sami ; Reddy, Utkarsh A. ; Reddy, Geereddy Bhanuprakash ; Ingle, Kundane ; Reddy, Mannem Rajeswara ; Aidhen, Indrapal Singh

Inspired from natural product isoliquiritine, an O‐glucoside and the corresponding aglycon chalcone, isoliquiritigenin (ISL), several C‐glucosylated chalcones and dihydrochalcones have been synthesized and evaluated for aldose reductase (AR) inhibition activity, for the first time. The initial inputs from molecular docking studies were also encouraging. Claisen‐Schmidt condensation reaction between 4‐C‐glucosylated benzaldehyde, a key building block developed during the synthetic efforts and acetophenones enabled convenient access to the targeted compounds in good yields. Excellent AR inhibition has been observed with C‐glucosylated ISL with IC50 value of 21 µM. This is similar to the chalcone ISL, displaying IC50 of 19 µM. In the light of limited aqueous solubility of ISL, the observed AR inhibition with C‐glucosylated ISL, gains importance. Additionally, the studies have revealed significance of the oxygenation pattern on the aromatic residue and paved way for the identification of few more new compounds with equally promising AR inhibition.

01 Feb 2016·ChemosphereQ2 · ENVIRONMENTAL SCIENCE & ECOLOGY

3D QSAR studies of hydroxylated polychlorinated biphenyls as potential xenoestrogens

Q2 · ENVIRONMENTAL SCIENCE & ECOLOGY

Article

Author: Ingale, Kundan ; Ruiz, Patricia ; Mumtaz, Moiz ; Wheeler, John S

Mono-hydroxylated polychlorinated biphenyls (OH-PCBs) are found in human biological samples and lack of data on their potential estrogenic activity has been a source of concern. We have extended our previous in silico 2D QSAR study through the application of advance techniques such as docking and 3D QSAR to gain insights into their estrogen receptor (ERα) binding. The results support our earlier findings that the hydroxyl group is the most important feature on the compounds; its position, orientation and surroundings in the structure are influential for the binding of OH-PCBs to ERα. This study has also revealed the following additional interactions that influence estrogenicity of these chemicals (a) the aromatic interactions of the biphenyl moieties with the receptor, (b) hydrogen bonding interactions of the p-hydroxyl group with key amino acids ARG394 and GLU353, (c) low or no electronegative substitution at para-positions of the p-hydroxyl group, (d) enhanced electrostatic interactions at the meta position on the B ring, and (e) co-planarity of the hydroxyl group on the A ring. In combination the 2D and 3D QSAR approaches have led us to the support conclusion that the hydroxyl group is the most important feature on the OH-PCB influencing the binding to estrogen receptors, and have enhanced our understanding of the mechanistic details of estrogenicity of this class of chemicals. Such in silico computational methods could serve as useful tools in risk assessment of chemicals.

03 Jan 2014·FEBS LettersQ3 · BIOLOGY

Identification of a novel ATPase activity in 14‐3‐3 proteins – Evidence from enzyme kinetics, structure guided modeling and mutagenesis studies

Q3 · BIOLOGY

Article

Author: Mukhopadhyay, Sami ; Nanaware, Padma P ; Somavarapu, Arun Kumar ; Venkatraman, Prasanna ; Ramteke, Manoj P ; Ramamoorthy, Vidhya ; Gautam, Amit Kumar Singh ; Karanam, Sudheer ; Shelke, Pradnya

14‐3‐3 Proteins bind phosphorylated sequences in proteins and regulate multiple cellular functions. For the first time, we show that pure recombinant human 14‐3‐3 ζ, γ, ε and τ isofoms hydrolyze ATP with similar Km and kcat values. In sharp contrast the sigma isoform has no detectable activity. Docking studies identify two putative binding pockets in 14‐3‐3 zeta. Mutation of D124A in the amphipathic pocket enhances binding affinity and catalysis. Mutation of a critical Arg (R55A) at the dimer interface in zeta reduces binding and decreases catalysis. These experimental results coincide with a binding pose at the dimer interface. This newly identified function could be a moon lighting function in some of these isoforms.

100 Deals associated with NovaLead Pharma Pvt Ltd.

Login to view more data

100 Translational Medicine associated with NovaLead Pharma Pvt Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

3

Preclinical

Approved

1

22

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Esmolol Hydrochloride ( β1-adrenergic receptor )	Diabetic foot ulcer More	Approved
NLP-21	COVID-19 More	Preclinical
NLP-91	Psoriasis More	Preclinical
NLP-328	Varicose Ulcer More	Preclinical
NLP-787	Eczema More	Discovery